Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
Pranabashis Haldar Respiratory Biomedical Research Unit, Glenfield Hospital, University of Leicester, Leicester, UK Abstract: Mepolizumab (Nucala®) is an effective and specific anti-eosinophil molecular therapy that has recently been approved as add-on therapy for the management of severe eo...
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Dove Medical Press
2017
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/111bf5d433994f3c93b4a3dfd6b4a85f |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Soyez le premier à ajouter un commentaire!